{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:58:44Z","timestamp":1780599524914,"version":"3.54.1"},"reference-count":41,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2018,8,19]],"date-time":"2018-08-19T00:00:00Z","timestamp":1534636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>After more than 28,000 Ebola virus disease cases and at least 11,000 deaths in West Africa during the 2014\u20132016 epidemic, the world remains without a licensed vaccine or therapeutic broadly available and demonstrated to alleviate suffering. This deficiency has been felt acutely in the two, short, following years with two Ebola virus outbreaks in the Democratic Republic of Congo (DRC), and a Marburg virus outbreak in Uganda. Despite billions of U.S. dollars invested in developing medical countermeasures for filoviruses in the antecedent decades, resulting in an array of preventative, diagnostic, and therapeutic products, none are available on commercial shelves. This paper explores why just-in-time research efforts in the field during the West Africa epidemic failed, as well as some recent initiatives to prevent similarly lost opportunities.<\/jats:p>","DOI":"10.3390\/v10080439","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T11:23:06Z","timestamp":1534764186000},"page":"439","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Catching Chances: The Movement to Be on the Ground and Research Ready before an Outbreak"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7583-8495","authenticated-orcid":false,"given":"David","family":"Brett-Major","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine and Biostatistics, F. Edward H\u00e9bert School of Medicine, Uniformed Services University, Bethesda, MD 20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lawler","sequence":"additional","affiliation":[{"name":"Global Center for Health Security, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,19]]},"reference":[{"key":"ref_1","unstructured":"WHO (2016). Situation Report: Ebola Virus Disease, WHO. Available online: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208883\/ebolasitrep_10Jun2016_eng.pdf?sequence=1."},{"key":"ref_2","unstructured":"WHO (2018). Ebola Virus Disease: Frequently Asked Questions on Compassionate Use of Investigational Vaccine for the Ebola Virus Disease Outbreak in Democratic Republic of the Congo, WHO. Available online: http:\/\/www.who.int\/ebola\/drc-2018\/faq-vaccine\/en\/."},{"key":"ref_3","unstructured":"Joellenbeck, L.M., Durch, J.S., and Benet, L.Z. (2004). Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures against Biological Warfare Agents, Institute of Medicine and National Research Council of the National Academies."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"The PREVAIL II Writing Group (2016). A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. N. Engl. J. Med., 375, 1448\u20131456.","DOI":"10.1056\/NEJMoa1604330"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., and Danel, C. (2016). Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., and Danel, C. (2016). Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., and Osman, H.K. (2016). Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1001997"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Camacho","year":"2015","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"Audran","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","unstructured":"OraSure Technologies, lnc (2016). Fact Sheet for Ebola Response Teams: Interpreting Results from the OraQuick\u00ae Ebola Rapid Antigen Test for Use with Cadaveric Oral Fluid, OraSure Technologies, lnc."},{"key":"ref_14","unstructured":"FDA (2018, August 04). CDER Drug and Biologic Animal Rule Approvals, Available online: https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/DrugandBiologicApprovalReports\/NDAandBLAApprovalReports\/UCM578137.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral Tecovirimat for the Treatment of Smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1073\/pnas.1401965111","article-title":"Genomic responses in mouse models greatly mimic human inflammatory diseases","volume":"112","author":"Takao","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","unstructured":"Various (2017). Communications on Filovirus Animal Non-clinical Group (FANG) Workshop, FANG."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1001\/archinternmed.2009.394","article-title":"Pooled analysis of rofecoxib placebo-controlled clinical trial data: Lessons for postmarket pharmaceutical safety surveillance","volume":"169","author":"Ross","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"j1909","DOI":"10.1136\/bmj.j1909","article-title":"Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data","volume":"357","author":"Bally","year":"2017","journal-title":"BMJ"},{"key":"ref_20","unstructured":"CDC (2018, August 04). Years of Ebola Virus Disease Outbreaks, Available online: https:\/\/www.cdc.gov\/vhf\/ebola\/history\/chronology.html."},{"key":"ref_21","unstructured":"Brett-Major, D.M. (2016). Sierra Leone. A Year of Ebola: A Personal Tale of the Weirdness Wrought by the World's Largest Ebola Virus Disease Epidemic, Navigating Health Risks, LLC."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(17)31795-6","article-title":"Evidence-based guidelines for supportive care of patients with Ebola virus disease","volume":"391","author":"Lamontagne","year":"2018","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13054-016-1325-2","article-title":"Ebola virus disease and critical illness","volume":"20","author":"Leligdowicz","year":"2016","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4269\/ajtmh.14-0746","article-title":"Being ready to treat Ebola virus disease patients","volume":"92","author":"Jacob","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_25","unstructured":"FIND (2014). Joint WHO\/FIND Meeting on Diagnostics and Ebola Control, World Health Organization & FIND."},{"key":"ref_26","unstructured":"WHO (2016). Ebola Response in Action, WHO. Available online: http:\/\/apps.who.int\/ebola\/our-work\/achievements."},{"key":"ref_27","unstructured":"WHO (2018). Ebola Virus Diseases: Democratic Republic of Congo: External Situation Report 6, World Health Organization."},{"key":"ref_28","unstructured":"Brett-Major, D.M. (2016). Navy, Health Security, and Insider Politics. A Year of Ebola: A Personal Tale of the Weirdness Wrought by the World's Largest Ebola Virus Disease Epidemic, Navigating Health Risks, LLC."},{"key":"ref_29","unstructured":"NAM (2016). The Neglected Dimension of Global Security: A Framework to Counter Infectious Disease Crises, The National Academies Press."},{"key":"ref_30","unstructured":"Brett-Major, S.M. (2007). Environmental Dispute Resolution: A Peaceable Kingdom, Columbus School of Law, Catholic University of America."},{"key":"ref_31","unstructured":"Frontieres, M.S. (2018, August 04). How We Work. Available online: https:\/\/www.msf.org\/how-we-work#ethics."},{"key":"ref_32","unstructured":"MSF (2018). Field Research, MSF. Available online: http:\/\/fieldresearch.msf.org\/msf\/."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Carazo Perez, S., Folkesson, E., Anglaret, X., Beavogui, A.-H., Berbain, E., Camara, A.-M., Depoortere, E., Lefevre, A., Maes, P., and Malme, K.N. (2017). Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005545"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Nguyen, T.H., Guedj, J., Anglaret, X., Laou\u00e9nan, C., Madelain, V., Taburet, A.M., Baize, S., Sissoko, D., Pastorino, B., and Rodallec, A. (2017). Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005389"},{"key":"ref_35","unstructured":"Corps, I.M. (2018, August 04). What We Do: Research. Available online: https:\/\/internationalmedicalcorps.org\/what-we-do\/our-approach\/research\/."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e000070","DOI":"10.1136\/bmjgh-2016-000070","article-title":"Validation of a portable, deployable system for continuous vital sign monitoring using a multiparametric wearable sensor and personalised analytics in an Ebola treatment centre","volume":"1","author":"Steinhubl","year":"2016","journal-title":"BMJ Glob. Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/cid\/cix290","article-title":"Ebola Virus Disease and Pregnancy: A Retrospective Cohort Study of Patients Managed at 5 Ebola Treatment Units in West Africa","volume":"65","author":"Henwood","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1473-3099(17)30112-3","article-title":"Characteristics and survival of patients with Ebola virus infection, malaria, or both in Sierra Leone: A retrospective cohort study","volume":"17","author":"Waxman","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_39","unstructured":"Sanders, N.L.J., Kibuuka, H., Martins, K., Cardile, A., Downey, L., Cando, C., Kolanko, C., Clark, D., Brett-Major, D., and Mimbe, D. (2017, January 6\u20138). Joint Mobile Emerging Disease Intervention Clinical Capability (JMEDICC): Integrating clinical research into outbreak response. (abstract-poster). Proceedings of the 2017 ASM Biodefense Conference, Washington, DC, USA."},{"key":"ref_40","unstructured":"NLM (2018). ClinicalTrials.gov: GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors with Evidence of Ebola Virus Persistence in Semen, [cited 10 July 2018]."},{"key":"ref_41","unstructured":"EC (2018). Platform for European Preparedness against (Re-)emerging Epidemics, EC. Available online: http:\/\/www.prepare-europe.eu\/."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/8\/439\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:19:33Z","timestamp":1760195973000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/10\/8\/439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,19]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["v10080439"],"URL":"https:\/\/doi.org\/10.3390\/v10080439","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,19]]}}}